Specific FRAX Programme at the WCO
All these presentations reflect scientific data obtained with the use of FRAX. FRAX is the trademark of the most widely validated and translated algorithm developed for the prediction of the 10-year individual fracture risk in men and women. The use of FRAX for individual fracture risk prediction is endorsed by IOF and ESCEO.
Friday April 17th - CEST Timezone
09:30
Auditorium 1
Oral communications selected from abstracts
OC1 - PREDICTIVE VALUE OF BMD FOR HIP AND OTHER FRACTURES: A META-ANALYSIS TO UPDATE FRAX
OC1 - PREDICTIVE VALUE OF BMD FOR HIP AND OTHER FRACTURES: A META-ANALYSIS TO UPDATE FRAX
11:10
Auditorium 1
Oral communications selected from abstracts
OC7 - REVISED SWEDISH FRAX MODELS AND THE ESTABLISHMENT OF AGE-DEPENDENT INTERVENTION THRESHOLDS
OC7 - REVISED SWEDISH FRAX MODELS AND THE ESTABLISHMENT OF AGE-DEPENDENT INTERVENTION THRESHOLDS
11:20
Auditorium 1
Oral communications selected from abstracts
OC8 - IMPROVED 10-YEAR FRACTURE RISK PREDICTION WITH THE “;BONE STRAIN INDEX“; BEYOND BONE MINERAL DENSITY AND FRAX IN COMMUNITY-DWELLING OLDER WOMEN
OC8 - IMPROVED 10-YEAR FRACTURE RISK PREDICTION WITH THE “;BONE STRAIN INDEX“; BEYOND BONE MINERAL DENSITY AND FRAX IN COMMUNITY-DWELLING OLDER WOMEN
Saturday April 18th - CEST Timezone
11:25
Auditorium 1
Oral communications selected from abstracts
OC25 - FOREARM BMD IS A FRAX INDEPENDENT PREDICTOR OF FRACTURE RISK
OC25 - FOREARM BMD IS A FRAX INDEPENDENT PREDICTOR OF FRACTURE RISK
11:55
Auditorium 1
Oral communications selected from abstracts
OC28 - PERFORMANCE OF NOGG GUIDELINES BASED ON FRAX PRIOR TO DXA VS FRAX CALCULATED USING A FEMORAL NECK ESTIMATE FROM AN OPPORTUNISTIC SCREEN OF LOW BONE DENSITY FROM STANDARD X-RAY
OC28 - PERFORMANCE OF NOGG GUIDELINES BASED ON FRAX PRIOR TO DXA VS FRAX CALCULATED USING A FEMORAL NECK ESTIMATE FROM AN OPPORTUNISTIC SCREEN OF LOW BONE DENSITY FROM STANDARD X-RAY
14:00 - 15:00
MR- D4
Educational Lecture: CKD-Associated Osteoporosis: The Overlooked Burden of Bone Fragility in CKD
Chairpersons: Maria Fusaro, Nicholas Harvey
Chairpersons: Maria Fusaro, Nicholas Harvey
14:00
MR- D4
Denosumab use in advanced CKD patients: yes or no, this is the dilemma
14:00
MR- D4
Mendelian randomization role of vitamin D in coronary heart disease
14:00
MR- D4
Bone quality in CKD: How to assess and why it matters
14:00
MR- D4
KIDNEY-FRAX: Is it the right time to perform it?